CA
NZ
UK
AU
IND
US
…
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -25.45M | -35.05M | -10.62M | -5.06M | -6.62M |
| Net income | -25.26M | -34.93M | -10.13M | -4.77M | -6.20M |
| Selling general administrative | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M |
| Gross profit | -25.65M | -35.73M | -10.01M | -5.75M | -4.32M |
| Ebit | -25.77M | -34.09M | -10.01M | -5.75M | -4.32M |
| Ebitda | -25.77M | -34.76M | -10.61M | -5.15M | -4.42M |
| Depreciation and amortization | -25.53M | -0.67M | -0.60M | 0.60M | -0.10M |
| Operating income | -51.29M | -34.09M | -10.01M | -5.75M | -4.32M |
| Other operating expenses | 51.29M | 34.09M | 10.01M | 5.75M | 4.32M |
| Interest expense | 0.32M | 0.29M | 0.01M | 0.02M | 2.19M |
| Tax provision | -0.18M | -0.12M | -0.49M | -0.29M | -0.41M |
| Interest income | 0.12M | 0.01M | - | - | - |
| Net interest income | -0.19M | -0.27M | -0.01M | -0.02M | -2.19M |
| Income tax expense | -0.19M | -0.12M | -0.49M | -0.29M | -0.41M |
| Total revenue | 0.00M | -1.64M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 25.65M | 34.09M | 10.01M | 5.75M | 4.32M |
| Cost of revenue | 25.65M | 35.73M | 10.01M | 5.75M | 4.32M |
| Total other income expense net | 25.84M | -0.96M | -0.61M | 0.69M | -2.29M |
| Net income from continuing ops | -25.26M | -34.93M | -10.13M | -4.77M | -6.20M |
| Net income applicable to common shares | - | -34.93M | -10.13M | -4.77M | -6.20M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 11.80M | 4.98M | 12.87M | 9.81M | 3.14M |
| Other current assets | 0.30M | 0.44M | 0.09M | 0.41M | 0.28M |
| Total liab | 16.51M | 13.03M | 2.66M | 1.36M | 1.76M |
| Total stockholder equity | -4.71M | -8.05M | 10.21M | 8.45M | 1.39M |
| Other current liab | 1.38M | 3.32M | 2.02M | 0.81M | 1.05M |
| Common stock | - | 0.00M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.00M | 0.00M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -125.50M | -91.09M | -56.16M | -46.03M | -41.26M |
| Other assets | - | 3.20M | 0.59M | 0.00M | 0.05M |
| Cash | 2.58M | 1.28M | 11.87M | 9.02M | 2.45M |
| Total current liabilities | 12.32M | 7.83M | 2.66M | 1.36M | 1.76M |
| Net debt | 2.62M | 5.56M | -11.87M | -9.02M | -2.33M |
| Short term debt | 1.00M | 1.65M | - | - | 0.12M |
| Short long term debt | 1.00M | 1.65M | - | - | 0.12M |
| Short long term debt total | 5.19M | 6.84M | - | - | 0.12M |
| Other stockholder equity | 120.04M | 82.28M | 66.23M | 54.85M | 42.33M |
| Total current assets | 3.06M | 1.78M | 12.28M | 9.76M | 3.09M |
| Net tangible assets | - | -8.05M | 10.21M | 8.45M | 1.39M |
| Net receivables | 0.18M | 0.05M | 0.32M | 0.32M | 0.36M |
| Long term debt | 4.19M | 5.19M | - | - | - |
| Accounts payable | 9.94M | 2.87M | 0.64M | 0.55M | 0.60M |
| Accumulated other comprehensive income | 0.74M | 0.76M | 0.13M | -0.38M | 0.30M |
| Common stock total equity | - | - | - | 0.01M | 0.01M |
| Non currrent assets other | 8.74M | 3.20M | 0.59M | 0.06M | 0.05M |
| Non current assets total | 8.74M | 3.20M | 0.59M | 0.06M | 0.05M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 0.40M | -0.66M | -0.54M | - | - |
| Change to liabilities | - | 2.25M | 0.63M | -0.75M | 0.30M |
| Total cashflows from investing activities | 0.40M | -0.66M | -0.54M | -0.54M | -0.54M |
| Net borrowings | -1.65M | - | - | -0.76M | 0.63M |
| Total cash from financing activities | 26.14M | 5.35M | 10.10M | 10.44M | 3.78M |
| Change to operating activities | - | -1.90M | 1.46M | 0.56M | -0.08M |
| Net income | -25.26M | -34.93M | -10.13M | -4.77M | -6.20M |
| Change in cash | 1.29M | -10.58M | 2.85M | 6.57M | 1.04M |
| Begin period cash flow | 1.28M | 11.87M | 9.02M | 2.45M | 1.41M |
| End period cash flow | 2.58M | 1.28M | 11.87M | 9.02M | 2.45M |
| Total cash from operating activities | -25.25M | -15.28M | -6.70M | -3.85M | -2.74M |
| Issuance of capital stock | 23.05M | 5.35M | 9.05M | 11.08M | 3.16M |
| Depreciation | - | - | - | 0.11M | 2.07M |
| Other cashflows from investing activities | 0.40M | - | -0.54M | -0.54M | -0.54M |
| Change to account receivables | -0.13M | - | - | -0.00M | - |
| Sale purchase of stock | -0.01M | - | - | - | - |
| Other cashflows from financing activities | 4.75M | 0.01M | 1.04M | 0.22M | 0.81M |
| Change to netincome | - | 19.10M | 1.29M | 1.10M | 1.20M |
| Capital expenditures | 0.00M | 0.66M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.65M | 0.56M | 2.14M | -0.19M | 0.19M |
| Stock based compensation | 0.82M | 1.09M | 1.29M | 1.21M | 1.09M |
| Other non cash items | -0.16M | 18.01M | 5.93M | -0.10M | 2.18M |
| Free cash flow | -25.25M | -15.94M | -6.70M | -3.85M | -2.74M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| PBLA Panbela Therapeutics Inc |
- -% |
0.00 | - | - | - | 3.22 | -0.22 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D. | CEO, Pres & Director | 1968 |
| Ms. Susan Horvath | VP of Fin., CFO, Sec. & Treasurer | 1959 |
| Ms. Tammy Groene | VP of Operations | NA |
| Dr. Elizabeth Bruckheimer Ph.D. | VP & Chief Scientific Officer | NA |
| Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. | CEO, President & Director | 1968 |
| Ms. Susan Horvath | VP of Finance, CFO, Secretary & Treasurer | 1959 |
| Ms. Tammy Groene | Vice President of Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...